Literature DB >> 29023938

A Pharmacist-Led Program to Evaluate and Reduce Polypharmacy and Potentially Inappropriate Prescribing in Older HIV-Positive Patients.

Ian R McNicholl1, Monica Gandhi2, C Bradley Hare3, Meredith Greene4, Edgar Pierluissi5.   

Abstract

OBJECTIVE: The goal of this pharmacist-led study was to utilize two validated instruments, Beers Criteria and Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP), to assess potentially inappropriate prescribing (PIP) in older patients infected with the human immunodeficiency virus (HIV) and evaluate pharmacist interventions.
DESIGN: Prospective randomized interventional trial.
SETTING: Large urban clinic providing interdisciplinary primary and HIV care for ~2700 HIV-positive publicly insured patients. DATA SOURCE: A computerized electronic record search was conducted for all patients who met the two search criteria: 50 years and older, and a primary care appointment within the last 12 months. PATIENTS: After identification of 857 patients meeting the search criteria, 324 patients were randomly selected and contacted, resulting in 248 patients assessed.
MEASUREMENTS AND MAIN RESULTS: Patients had a mean age of 58 years, 71% male, 44% white, and a mean CD4 count of 536 cells/mm3 . Common comorbidities included hypertension (56%), depression (52%), asthma/chronic obstructive pulmonary disease (48%), dyslipidemia (39%), coronary artery disease (27%), and diabetes (22%). Patients sampled were prescribed a mean of 11.6 ± 5.7 concomitant medications (excluding antiretrovirals) with 35% receiving at least 16 medications. PIP was identified in 54% and 63% of patients using the STOPP and Beers Criteria, respectively. Twenty-five contraindicated drug interactions were identified in 20 patients. After the pharmacist visit, at least 69% of patients had at least one medication discontinued with almost 10% having six or more medications discontinued. More than 40% of patients had at least one Beers or STOPP criteria that required immediate correction by the pharmacist.
CONCLUSIONS: Results suggest that targeting individuals with 11 or more chronic medications would have the highest yield and greatest impact. Pharmacist-led review of medication prescribing using Beers and STOPP criteria revealed a large number of PIP, many amenable to immediate clinical pharmacist intervention.
© 2017 Pharmacotherapy Publications, Inc.

Entities:  

Keywords:  zzm321990HIVzzm321990; zzm321990STOPPzzm321990; Beers; aging; older; pharmacist; polypharmacy; potentially inappropriate prescribing

Mesh:

Year:  2017        PMID: 29023938     DOI: 10.1002/phar.2043

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  22 in total

1.  Older HIV-infected adults. Complex patients (III): Polypharmacy.

Authors:  Samuel F Freedman; Carrie Johnston; John J Faragon; Eugenia L Siegler; Tessa Del Carmen
Journal:  Eur Geriatr Med       Date:  2018-12-06       Impact factor: 1.710

2.  Ritonavir-Boosted Protease Inhibitors but Not Cobicistat Appear Safe in HIV-Positive Patients Ingesting Dabigatran.

Authors:  Payal P Kakadiya; Patricia Pecora Fulco; Robert T Higginson
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

3.  Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis.

Authors:  Amanda M Kong; Alexis Pozen; Kathryn Anastos; Elizabeth A Kelvin; Denis Nash
Journal:  AIDS Patient Care STDS       Date:  2019-03       Impact factor: 5.078

4.  Risk Factors for Falls, Falls With Injury, and Falls With Fracture Among Older Men With or at Risk of HIV Infection.

Authors:  Kristine M Erlandson; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

Review 5.  Deprescribing of non-antiretroviral therapy in HIV-infected patients.

Authors:  José-Ramón Blanco; Ramón Morillo; Vicente Abril; Ismael Escobar; Enrique Bernal; Carlos Folguera; Fátima Brañas; Mercedes Gimeno; Olatz Ibarra; José-Antonio Iribarren; Alicia Lázaro; Ana Mariño; María-Teresa Martín; Esteban Martinez; Luis Ortega; Julian Olalla; Aguas Robustillo; Matilde Sanchez-Conde; Miguel-Angel Rodriguez; Javier de la Torre; Javier Sanchez-Rubio; Montse Tuset
Journal:  Eur J Clin Pharmacol       Date:  2019-12-21       Impact factor: 2.953

6.  Impact and acceptance of pharmacist-led interventions during HIV care in a third-level hospital in Spain using the Capacity-Motivation-Opportunity pharmaceutical care model: the IRAFE study.

Authors:  M Gracia Cantillana-Suárez; Maria de Las Aguas Robustillo-Cortés; Antonio Gutiérrez-Pizarraya; Ramón Morillo-Verdugo
Journal:  Eur J Hosp Pharm       Date:  2021-02-24

Review 7.  Frailty and HIV: Moving from Characterization to Intervention.

Authors:  Kristine M Erlandson; Damani A Piggott
Journal:  Curr HIV/AIDS Rep       Date:  2021-04-05       Impact factor: 5.495

8.  A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study.

Authors:  E Jennifer Edelman; James Dziura; Yanhong Deng; Krysten W Bold; Sean M Murphy; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein
Journal:  Contemp Clin Trials       Date:  2021-03-29       Impact factor: 2.226

9.  Current Challenges and Solutions in Research and Clinical Care of Older Persons Living with HIV: Findings Presented at the 9th International Workshop on HIV and Aging.

Authors:  Erin E Sundermann; Kristine M Erlandson; Caitlin N Pope; Anna Rubtsova; Jessica Montoya; Alison A Moore; Catia Marzolini; Kelly K O'Brien; Savita Pahwa; Brendan A I Payne; Leah H Rubin; Sharon Walmsley; Norman J Haughey; Monty Montano; Maile Y Karris; Joseph B Margolick; David J Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2019-09-10       Impact factor: 1.723

Review 10.  Polypharmacy in HIV: recent insights and future directions.

Authors:  E Jennifer Edelman; Christopher T Rentsch; Amy C Justice
Journal:  Curr Opin HIV AIDS       Date:  2020-03       Impact factor: 4.061

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.